R-wave Optimisation in Cardiac Resynchronisation Therapy Study

Overview

The aim of this study is to investigate whether the use of a simple feature on the 12 lead electrocardiogram (ECG) to optimise pacemaker device programming can have clinically relevant benefit to patient management. More specifically it is to investigate whether using the R-wave in V1 of the surface ECG to guide the timings between left (LV) and right ventricular (RV) pacing improves response to Cardiac Resynchronisation Therapy.

Full Title of Study: “Use of the R-wave to Optimise VV Delay in Heart Failure Patients Treated With Cardiac Resynchronisation Therapy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: March 2016

Interventions

  • Other: Optimisation of V-V timing using R wave on surface ECG
  • Other: Standard V-V timing settings

Arms, Groups and Cohorts

  • Experimental: Optimised V-V timing delay
    • V-V timing delay setting on biventricular pacemaker will be optimised guided by size of R-wave on surface ECG
  • Active Comparator: Standard V-V timing delay
    • Standard settings

Clinical Trial Outcome Measures

Primary Measures

  • Quality of Life Score
    • Time Frame: 3 months

Secondary Measures

  • 6 minute hall walk distance
    • Time Frame: 3 months
  • Left Ventricular End Systolic Volume Index
    • Time Frame: 3 months

Participating in This Clinical Trial

Inclusion Criteria

  • The patient must have a biventricular pacemaker in situ, implanted for NYHA Class III / IV heart failure syndrome with impaired systolic function. – Implantation indication must have included a left ventricular ejection fraction measured on transthoracic echo of <35% and either – a QRS duration of >150ms or – a QRS duration of 120 – 149ms with further evidence of dyssynchrony confirmed by echocardiography. – Participants must have >95% true biventricular pacing over the 1 month before enrolment and throughout the observation period. – The biventricular paced QRS complex morphology in lead V1 of subject's standard 12 lead surface ECG must show an R wave height of < 1mm or <20% of the total QRS deflection with standard LV offset settings applied. – The subject's standard 12 lead surface ECG must show a right bundle branch block pattern in lead V1 during LV only pacing. – The participant must be willing to comply with the protocol requirements including travelling to the Royal Bournemouth Hospital for the attendances required for the study and intend to have their long term device follow up at the Royal Bournemouth Hospital at the time of enrolment. – Provision of informed consent Exclusion criteria – Hypertrophic or restrictive cardiomyopathy – Suspected acute myocarditis – Correctable Valvulopathy – An Acute Coronary Syndrome within the last 3 months – Recent (within the last 3 months) or scheduled coronary revascularisation – Treatment resistant hypertension – Severe obstructive lung disease – Pregnancy at the time of enrolment or a desire to become pregnant during the study period – An inability to walk – Reduced life expectancy not associated with cardiovascular disease (less than 1 year) – Unable to provide informed consent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The Royal Bournemouth Hospital
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.